Gilead Sciences Stock Price

0.57 (0.9%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 6,814,570
Bid Price 63.57
Ask Price 64.00
News -
Day High 63.90


52 Week Range


Day Low 62.725
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Gilead Sciences Inc GILD NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.57 0.9% 63.84 20:00:00
Open Price Low Price High Price Close Price Prev Close
63.37 62.725 63.90 63.84 63.27
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
71,337 6,814,570 $ 63.22 $ 430,810,199 - 57.185 - 74.12
Last Trade Time Type Quantity Stock Price Currency
19:59:38 63 $ 64.00 USD


Draw Mode:

Gilead Sciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 80.08B 1.25B 1.26B $ 27.31B $ 4.43B 4.93 17.70
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ 2.84 4.62% 06/14/22 1.00M 0.60%

more financials information »

Gilead Sciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical GILD Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week62.6063.92561.5662.877,939,0241.241.98%
1 Month63.7863.92559.1561.688,700,0980.060.09%
3 Months60.8964.2857.18560.619,791,4242.954.84%
6 Months68.7074.1257.18564.239,601,486-4.86-7.07%
1 Year68.6674.1257.18566.077,976,586-4.82-7.02%
3 Years65.9989.0056.5668.179,342,579-2.15-3.26%
5 Years64.2489.5456.5669.798,650,169-0.40-0.62%

Gilead Sciences Description

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Your Recent History
Gilead Sci..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.